Influence from topical application of Rapydan before blood sampling on routine clinical chemistry en hematology measurements.

Completed

• Conditions: Pijnbestrijding voorafgaand aan een venapunctie of aanleggen infuus; pain

• Registration Number: NL-OMON33774
• Lead Sponsor: Medisch Laboratorium Noord

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 25

Inclusion Criteria

Healthy, not seriously ill, patient descision competent, not allergic for local anesthetics lidocain and tetracaïne

Exclusion Criteria

younger than 20 and older than 60
Hypersensitivity to the active substances(lidocaine and tetracaïne, to sodium borate or to any of the other excipients. Hypersensitivity to local anaesthetics of the amide or ester type or to para-aminobenzoic acid (by-product in tetracaine metabolism). Patients using Class I antiarrhythmic medicinal products (such as quinidine, disopyramide, tocainide and mexiletine) and class III antiarrhythmic medicinal products (e.g. amiodarone) or other products containing local anaesthetic agents.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Routine Clinical Chemistry measurements differences</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>not present</p><br>